Associated Genetic Biomarkers
PRKACA is altered in 0.13% of all cancers with fibrolamellar carcinoma, hepatocellular carcinoma, conventional glioblastoma multiforme, pancreatic adenocarcinoma, and adenocarcinoma of unknown primary having the greatest prevalence of alterations .
The most common alterations in PRKACA are PRKACA-DNAJB1 Fusion (0.03%), PRKACA A224V (0.09%), PRKACA A233V (0.07%), PRKACA A35T (0.07%), and PRKACA E108V (0.07%) .
PRKACA status serves as an inclusion eligibility criteria in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains PRKACA status as an inclusion criterion, 1 is phase 1 (1 open).
The most frequent alteration to serve as an inclusion eligibility criterion is DNAJB1-PRKACA Fusion .
Significance of PRKACA in Diseases
Fibrolamellar Carcinoma +
PRKACA is altered in 89.29% of fibrolamellar carcinoma patients .
PRKACA is an inclusion criterion in 1 clinical trial for fibrolamellar carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PRKACA status and fibrolamellar carcinoma as inclusion criteria, 1 is phase 1 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.